Pallavi B Rane
Overview
Explore the profile of Pallavi B Rane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skalicky A, Wang Y, Eseyin O, Stefan M, Rane P, McLaren J, et al.
J Patient Rep Outcomes
. 2024 Dec;
8(1):153.
PMID: 39718711
Objective: A key component of determining that a patient-reported outcome (PRO) measure is fit-for-purpose is to ensure that respondents understand its instructions and items. Any modification to a measure should...
2.
Camargo Jr C, Rane P, Beck A, Wang Y, Chung Y, McGuiness C, et al.
Ann Allergy Asthma Immunol
. 2023 Dec;
132(5):602-609.e4.
PMID: 38141810
Background: In the United States, a few studies have evaluated geographic variation of severe asthma at the subnational level. Objective: To assess state-level geographic variation in the prevalence and characteristics...
3.
Burnette A, Wang Y, Rane P, Chung Y, Princic N, Park J, et al.
J Manag Care Spec Pharm
. 2023 Jul;
29(7):825-834.
PMID: 37404066
The economic burden of severe asthma and severe uncontrolled asthma (SUA) is significant. Updated assessments of health care resource utilization (HCRU) and cost are needed given the increase in treatment...
4.
Fonarow G, Kosiborod M, Rane P, Nunna S, Villa G, Habib M, et al.
Clin Cardiol
. 2021 Aug;
44(10):1457-1466.
PMID: 34351003
Background: The risk for subsequent major cardiovascular (CV) events among patients with very high-risk (VHR) atherosclerotic CV disease (ASCVD) remains to be fully elucidated. Hypothesis: We assessed the characteristics and...
5.
Baum S, Rane P, Nunna S, Habib M, Philip K, Sun K, et al.
Am J Prev Cardiol
. 2021 Jul;
6:100177.
PMID: 34327500
Objective: We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion of patients with retrospectively identified...
6.
Feng X, Berklein F, Rane P, Habib M, Lin P
Cardiovasc Drugs Ther
. 2020 Jun;
35(5):965-973.
PMID: 32594283
Purpose: There is limited real-world evidence around use of proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i) among US older adults. This study examined baseline characteristics of fee-for-service (FFS) Medicare beneficiaries...
7.
Chen C, Rane P, Hines D, Patel J, Harrison D, Wade R
Ther Clin Risk Manag
. 2018 Dec;
14:2425-2435.
PMID: 30587999
Background: This study evaluated the proportion of patients with atherosclerotic cardiovascular disease (ASCVD) and probable heterozygous familial hypercholesterolemia (HeFH) achieving ≥50% reduction in low-density lipoprotein cholesterol (LDL-C) or reaching the...
8.
Rane P, Patel J, Harrison D, Shepherd J, Leith A, Bailey H, et al.
Am J Cardiovasc Drugs
. 2017 Aug;
18(2):103-108.
PMID: 28849360
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce low-density lipoprotein cholesterol (LDL-C) levels and are approved for patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional LDL-C...
9.
Chambers J, Rane P, Neumann P
Am J Manag Care
. 2016 Aug;
22(8):524-31.
PMID: 27541699
Objectives: In an attempt to increase the efficiency of their drug benefit policies, insurers are increasingly excluding drugs from their formularies that they deem to be of low value. Our...
10.
Rane P, Madhavan S, Sambamoorthi U, Sita K, Kurian S, Pan X
Popul Health Manag
. 2016 Jul;
20(1):55-65.
PMID: 27419662
The aim was to examine and compare with "national" estimates, receipt of colorectal cancer (CRC) treatment in the initial phase of care and survival following a CRC diagnosis in rural...